Concurrent gliomas in patients with multiple sclerosis.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
received:
22
12
2022
accepted:
10
10
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
epublish
Résumé
Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives. A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients. MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade 4 without isocitratdehydrogenase (IDH) mutations have a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade 2 receive multiple sclerosis diagnosis mostly at the same time or later. Concurrent MS is associated with a lesser extent of tumor resection and a worse prognosis in IDH-mutant glioma patients (PFS 32 vs. 64 months, p = 0.0206). When assessing tumor-intrinsic differences no distinct subgroup-defining methylation pattern is identified in gliomas of MS patients compared to other glioma samples. However, differential methylation of immune-related genetic loci including human leukocyte antigen locus on 6p21 and interleukin locus on 5q31 is found in MS patients vs. matched non-MS patients. In line, inflammatory disease activity increases in 42% of multiple sclerosis patients after brain tumor radiotherapy suggesting a susceptibility of multiple sclerosis brain tissue to pro-inflammatory stimuli such as ionizing radiation. Concurrent low-grade gliomas should be considered in multiple sclerosis patients with slowly progressive, expansive T2/FLAIR lesions. Our findings of typically reduced extent of resection in MS patients and increased MS activity after radiation may inform future treatment decisions. Brain tumors such as gliomas can evade attacks by the immune system. In contrast, some diseases of the central nervous system such as multiple sclerosis (MS) are caused by an overactive immune system. Our study looks at a cohort of rare patients with both malignant glioma and concurrent MS and examines how each disease and their treatments affect each other. Our data suggest that even in patients with known MS, if medical imaging findings are unusual, a concurrent brain tumor should be excluded at an early stage. Radiotherapy, as is the standard of care for malignant brain tumors, may worsen the inflammatory disease activity in MS patients, which may be associated with certain genetic risk factors. Our findings may help to inform treatment of patients with brain tumors and MS.
Sections du résumé
BACKGROUND
BACKGROUND
Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.
METHODS
METHODS
A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.
RESULTS
RESULTS
MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade 4 without isocitratdehydrogenase (IDH) mutations have a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade 2 receive multiple sclerosis diagnosis mostly at the same time or later. Concurrent MS is associated with a lesser extent of tumor resection and a worse prognosis in IDH-mutant glioma patients (PFS 32 vs. 64 months, p = 0.0206). When assessing tumor-intrinsic differences no distinct subgroup-defining methylation pattern is identified in gliomas of MS patients compared to other glioma samples. However, differential methylation of immune-related genetic loci including human leukocyte antigen locus on 6p21 and interleukin locus on 5q31 is found in MS patients vs. matched non-MS patients. In line, inflammatory disease activity increases in 42% of multiple sclerosis patients after brain tumor radiotherapy suggesting a susceptibility of multiple sclerosis brain tissue to pro-inflammatory stimuli such as ionizing radiation.
CONCLUSIONS
CONCLUSIONS
Concurrent low-grade gliomas should be considered in multiple sclerosis patients with slowly progressive, expansive T2/FLAIR lesions. Our findings of typically reduced extent of resection in MS patients and increased MS activity after radiation may inform future treatment decisions.
Brain tumors such as gliomas can evade attacks by the immune system. In contrast, some diseases of the central nervous system such as multiple sclerosis (MS) are caused by an overactive immune system. Our study looks at a cohort of rare patients with both malignant glioma and concurrent MS and examines how each disease and their treatments affect each other. Our data suggest that even in patients with known MS, if medical imaging findings are unusual, a concurrent brain tumor should be excluded at an early stage. Radiotherapy, as is the standard of care for malignant brain tumors, may worsen the inflammatory disease activity in MS patients, which may be associated with certain genetic risk factors. Our findings may help to inform treatment of patients with brain tumors and MS.
Autres résumés
Type: plain-language-summary
(eng)
Brain tumors such as gliomas can evade attacks by the immune system. In contrast, some diseases of the central nervous system such as multiple sclerosis (MS) are caused by an overactive immune system. Our study looks at a cohort of rare patients with both malignant glioma and concurrent MS and examines how each disease and their treatments affect each other. Our data suggest that even in patients with known MS, if medical imaging findings are unusual, a concurrent brain tumor should be excluded at an early stage. Radiotherapy, as is the standard of care for malignant brain tumors, may worsen the inflammatory disease activity in MS patients, which may be associated with certain genetic risk factors. Our findings may help to inform treatment of patients with brain tumors and MS.
Identifiants
pubmed: 38110626
doi: 10.1038/s43856-023-00381-y
pii: 10.1038/s43856-023-00381-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
186Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 39404578
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 39404578
Organisme : Gemeinnützige Hertie-Stiftung (Hertie Foundation)
ID : P1200013
Organisme : Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)
ID : 2019_EKMS.23
Informations de copyright
© 2023. The Author(s).
Références
Sinclair, G., Al-Saffar, Y., Johnstone, P., Hatiboglu, M. A. & Shamikh, A. A challenging case of concurrent multiple sclerosis and anaplastic astrocytoma. Surgical Neurol. Int. 10, 166–166 (2019).
doi: 10.25259/SNI_176_2019
Preziosa, P. et al. Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. Neurol. Sci. 38, 361–364 (2017).
doi: 10.1007/s10072-016-2763-y
pubmed: 27837369
Plantone, D., Renna, R., Sbardella, E. & Koudriavtseva, T. Concurrence of multiple sclerosis and brain tumors. Front. Neurol. 6, 40 (2015).
doi: 10.3389/fneur.2015.00040
pubmed: 25788892
pmcid: 4349169
Acqui, M., Caroli, E., Di Stefano, D. & Ferrante, L. Cerebral ependymoma in a patient with multiple sclerosis case report and critical review of the literature. Surg. Neurol. 70, 414–420 (2008).
doi: 10.1016/j.surneu.2007.04.015
pubmed: 18295851
Sierra Morales, F. et al. Glioblastoma in natalizumab-treated multiple sclerosis patients. Ann. Clin. Transl. Neurol. 4, 512–516 (2017).
doi: 10.1002/acn3.428
pubmed: 28695151
pmcid: 5497532
Sharim, J., Tashjian, R., Golzy, N. & Pouratian, N. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. J. Clin. Neurosci. 30, 166–168 (2016).
doi: 10.1016/j.jocn.2016.02.003
pubmed: 26970935
pmcid: 4925177
Mantero, V. et al. Brainstem glioblastoma in a patient with secondary progressive multiple sclerosis. Neurol. Sci. 36, 1733–1735 (2015).
doi: 10.1007/s10072-015-2256-4
pubmed: 25990103
Anssar, T. M. et al. Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. Cancer Med. 9, 1263–1275 (2020).
doi: 10.1002/cam4.2767
pubmed: 31821741
Hemminki, K. et al. Subsequent brain tumors in patients with autoimmune disease. Neuro Oncol. 15, 1142–1150 (2013).
doi: 10.1093/neuonc/not070
pubmed: 23757294
pmcid: 3748918
Kebir, S. et al. F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report. Oncol. Lett. 11, 2195–2198 (2016).
doi: 10.3892/ol.2016.4189
pubmed: 26998148
pmcid: 4774557
Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682–694 (2017).
doi: 10.1016/S1470-2045(17)30155-9
pubmed: 28314689
Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature. 555, 469–474 (2018).
doi: 10.1038/nature26000
pubmed: 29539639
pmcid: 6093218
Celarain, N. & Tomas-Roig, J. Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients. J. Neuroinflammation 17, 21 (2020).
doi: 10.1186/s12974-019-1667-1
pubmed: 31937331
pmcid: 6961290
Huynh, J. L. et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat. Neurosci. 17, 121–130 (2014).
doi: 10.1038/nn.3588
pubmed: 24270187
Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).
doi: 10.1016/S1474-4422(17)30470-2
pubmed: 29275977
Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).
doi: 10.1200/JCO.2009.26.3541
pubmed: 20231676
van den Bent, M. J. et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 12, 583–593 (2011).
doi: 10.1016/S1470-2045(11)70057-2
pubmed: 21474379
Kessler, T. et al. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro Oncol. 20, 367–379 (2018).
doi: 10.1093/neuonc/nox160
pubmed: 29016808
Wick, W. et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 18, 1529–1537 (2016).
pubmed: 27370396
pmcid: 5063521
Van Den Bent, M. J. et al. Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. J. Clin. Oncol. (2019).
Klein, J. & Sato, A. The HLA system. First of two parts. N. Engl. J. Med. 343, 702–709 (2000).
doi: 10.1056/NEJM200009073431006
pubmed: 10974135
Gourraud, P. A., Harbo, H. F., Hauser, S. L. & Baranzini, S. E. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 248, 87–103 (2012).
doi: 10.1111/j.1600-065X.2012.01134.x
pubmed: 22725956
pmcid: 5967887
Aarli, J. A., Mørk, S. J., Myrseth, E. & Larsen, J. L. Glioblastoma associated with multiple sclerosis: coincidence or induction? Eur. Neurol. 29, 312–316 (1989).
doi: 10.1159/000116437
pubmed: 2691257
Currie, S. & Urich, H. Concurrence of multiple sclerosis and glioma. J. Neurol. Neurosurg. Psychiatry 37, 598–605 (1974).
doi: 10.1136/jnnp.37.5.598
pubmed: 4365433
pmcid: 494706
Frisullo, G. et al. Glioblastoma in multiple sclerosis: a case report. J. Neurooncol. 94, 141–144 (2009).
doi: 10.1007/s11060-009-9804-9
pubmed: 19214706
Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)−2-hydroxyglutarate. Nat. Med. 24, 1192–1203 (2018).
doi: 10.1038/s41591-018-0095-6
pubmed: 29988124
Mildenberger, I., Bunse, L., Ochs, K. & Platten, M. The promises of immunotherapy in gliomas. Curr. Opin. Neurol. 30, 650–658 (2017).
doi: 10.1097/WCO.0000000000000491
pubmed: 28984704
Platten, M. et al. Vaccine strategies in gliomas. Curr. Treat Options Neurol. 20, 11 (2018).
doi: 10.1007/s11940-018-0498-1
pubmed: 29594595
Hinnell, C. et al. Concurrence of high-grade brainstem glioma and multiple sclerosis. Can. J. Neurol. Sci. 37, 512–514 (2010).
doi: 10.1017/S0317167100010556
pubmed: 20724261
Dobson, R. & Giovannoni, G. Multiple sclerosis - a review. Eur. J. Neurol. 26, 27–40 (2019).
doi: 10.1111/ene.13819
pubmed: 30300457
Green, A. J., Bollen, A. W., Berger, M. S., Oksenberg, J. R. & Hauser, S. L. Multiple sclerosis and oligodendroglioma. Mult. Scler. 7, 269–273 (2001).
doi: 10.1177/135245850100700410
pubmed: 11548988
Tabatabaei, P. et al. Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study. J. Neurooncol. 131, 83–92 (2017).
doi: 10.1007/s11060-016-2271-1
pubmed: 27664151
Reznik, E. et al. Radiation and immunotherapy in high-grade gliomas: where do we stand? Am. J. Clin. Oncol. 41, 197–212 (2018).
doi: 10.1097/COC.0000000000000406
pubmed: 28906259